Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor agonist approved for treating obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiencies, as well as Bardet-Biedl and Alström syndromes. The company is also investigating IMCIVREE in Phase 3 trials for acquired and congenital hypothalamic obesity, and in Phase 2 trials for Prader-Willi syndrome and MC4R deficiency. Additionally, Rhythm is developing bivamelagon, an oral small molecule MC4R agonist in Phase 2 for MC4R pathway diseases, and RM-718, a next-generation MC4R peptide agonist in Phase 1 for hypothalamic obesity.

Rhythm Pharmaceuticals is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol RYTM. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Boston, Massachusetts, and its stock is accessible to investors through major US brokerages and international platforms that offer Nasdaq-listed securities.

Rhythm Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on discovering, developing, and commercializing innovative therapies for rare diseases, particularly those involving the melanocortin-4 receptor (MC4R) pathway. Its work bridges cutting-edge biotechnology and clinical medicine to address unmet needs in rare neuroendocrine conditions, such as genetic obesity disorders and hypothalamic obesity.

Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts, United States. The company serves patients and healthcare providers in the United States and globally. Its lead product, IMCIVREE, is approved in the US and other regions for certain rare obesity disorders, and the company is conducting clinical trials worldwide to expand its reach. Rhythm's focus on rare neuroendocrine diseases means its market includes specialized treatment centers and genetic testing programs across multiple countries.

Rhythm Pharmaceuticals generates revenue primarily through the commercialization of IMCIVREE (setmelanotide), its approved therapy for rare genetic obesity disorders. The company also advances a pipeline of investigational candidates: bivamelagon, an oral small molecule MC4R agonist in Phase 2 trials for MC4R pathway diseases, and RM-718, a next-generation MC4R peptide agonist in Phase 1 for hypothalamic obesity. Additionally, Rhythm is conducting Phase 3 trials for IMCIVREE in acquired and congenital hypothalamic obesity, and Phase 2 trials for Prader-Willi syndrome and MC4R deficiency. Revenue growth depends on expanding approved indications and successful clinical development.